Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.

Yonsei medical journal - 1 Jan 2013

Saijo Nagahiro

Abstract excerpt

The effective and toxic ranges of anticancer drugs are very narrow and, in some cases, inverted. Thus determination of the most appropriate dosage and schedule of administration is crucial for optimal chemotherapy. In common arm trials conducted in Japan and by Southwest Oncology Group (SWOG) that used the same doses and schedules for the administration of carboplatin plus paclitaxel, the frequency of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Drug Design

Share to Ethnicity

Share to Lung Diseases, Interstitial

Share to Pharmacogenetics

Share to Republic of Korea

Source

Open in PubMed Open full text

Identifiers

PMID: 23225792
DOI: 10.3349/ymj.2013.54.1.1
PMCID: PMC3521281

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology.PMID 23225792Read ↗

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related PharmacogenomicsSemantic proximity Read ↗

Population-based differences in treatment outcome following anticancer drug therapies.Semantic proximity Read ↗

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Semantic proximity Read ↗

Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.Semantic proximity Read ↗

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.Semantic proximity Read ↗

[Difference in Chemotherapy for Lung Cancer between Asian and Caucasian].Semantic proximity Read ↗

Highlights from the latest articles in pharmacogenomics of irinotecan/cisplatin toxicity.Semantic proximity Read ↗

Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan.Semantic proximity Read ↗

Can population differences in chemotherapy outcomes be inferred from differences in pharmacogenetic frequencies?Semantic proximity Read ↗

Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy.Semantic proximity Read ↗

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism.Semantic proximity Read ↗

Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.